MarketPulse
I

$IONS

8 articles found
6 positive
0 negative
2 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Complement Inhibitors Market Set for Robust Growth Through 2036 as C5, C3 Therapies Expand

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.
NVSSNYRHHBYAZNREGN+3clinical trialsmarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

IgA Nephropathy Market Set to Nearly Quadruple by 2036 Amid Novel Therapy Wave

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.
NVSVRTXRHHBYAZNTAK+4clinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Polycythemia Vera Market Poised for Major Expansion as Nine Pharma Giants Rush New Therapies

Polycythemia vera market expected to expand 8.9% CAGR through 2036 from $2B base as nine pharma companies advance novel therapies, with rusfertide entering first.
MRKPTGXIRONTAKIONS+1clinical trialsmarket expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Praxis Precision Medicines Posts Breakthrough Results for Rare Epilepsy Gene Therapy

Praxis reports 77% placebo-adjusted seizure reduction in SCN2A epilepsy treatment with no serious safety events, advancing precision neurotherapy.
PRAXIONSclinical trialprecision medicine
BenzingaBenzinga··Vandana Singh

Ionis Slashes Tryngolza Price 93% Ahead of FDA Label Expansion Decision

Ionis Pharmaceuticals cuts Tryngolza price from $595K to $40K annually, positioning for broader FDA approval and potential $2B+ peak sales.
IONSFDA approvalmarket expansion
Investing.comInvesting.com··Thomas Hughes

Insider Selling as a Contrarian Signal: Why $WM and $IONS Merit Investor Attention

Insider selling at $WM and $IONS masks attractive opportunities as institutional accumulation and strong fundamentals validate contrarian bullish cases for both stocks.
WMIONSdividend growthprofit-taking
The Motley FoolThe Motley Fool··Jonathan Ponciano

Boone Capital Exits 372% Biotech Winner to Chase Emerging Clinical Plays

Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.
MDTTYRAIONSCOGTBMRN+2biotechclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Custom Market Insights

ALS Therapeutics Market Poised to More Than Double by 2035

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.
CYTKBIIBIONSAMLXrare diseasegene therapy